Moderna Chairman Noubar Afeyan says the trial results remind him of when his company developed its Covid-19 vaccine.
Moderna shares soared 172% after strong results for its vaccine for melanoma skin cancer. Elsewhere, the Evergrande saga came ...
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
CNBC's Kristina Partsinevelos joins 'Closing Bell' to discuss the stocks she's watching.
Billionaire biotech pioneer Robert Langer advises workers to do what makes them happy over money and job security: “If you ...
CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay ...
A personalized mRNA vaccine for melanoma reduced the risk of the cancer returning in a phase III clinical trial, the ...
1dOpinion
Moderna’s Road to a Cancer Vaccine
The company says a trial met its goal to prevent melanoma recurrence.
An mRNA success is something of a vindication for Trump (and the Biden years), but an embarrassment for RFK Jr.
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage ...
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results